-

Abiomed Second Quarter Fiscal 2023 Earnings and Conference Call Notification

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed, Inc. (NASDAQ: ABMD) announced that on Tuesday, November 1, 2022, the Company will release financial results for the second quarter of the fiscal year 2023. The Company will host a conference call to discuss the results on Tuesday, November 1, 2022 at 8:00 a.m. ET. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief Financial Officer, will host the conference call.

To listen to the call live, please tune into the webcast via https://events.q4inc.com/attendee/493387843 or dial (844) 200-6205; the international number is (929) 526-1599 access code 367357. A replay of this conference call will be available until Tuesday, November 8, 2022. The replay phone number is (866) 813- 9403; the international number is +44 204 525 0658.

ABOUT ABIOMED
Based in Danvers, Massachusetts, USA, Abiomed (ABMD), is a leading provider of medical technology that provides circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit: www.abiomed.com.

FORWARD-LOOKING STATEMENTS

Any forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts

For further information, please contact:
Todd Trapp
Chief Financial Officer
978-646-1680
ttrapp@abiomed.com

Abiomed, Inc.

NASDAQ:ABMD

Release Summary
Abiomed announces second quarter fiscal 2023 earnings and conference call.
Release Versions

Contacts

For further information, please contact:
Todd Trapp
Chief Financial Officer
978-646-1680
ttrapp@abiomed.com

More News From Abiomed, Inc.

FDA Approves Impella ECP Pivotal Heart Pump and First Patients Enrolled in Pivotal Clinical Trial

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed Announces First Patients Enrolled in FDA Pivotal Trial for Impella ECP, World’s Smallest Heart Pump...

First Patients in the World Treated with Impella RP Flex with SmartAssist

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces the first three patients in the world have been treated with Impella RP Flex with SmartAssist....

Abiomed Announces Second Quarter Revenue of $266 Million, up 11% in Constant Currency*, up 7% on a Reported Basis Year Over Year

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed today announces financial results for the quarter ended September 30, 2022....
Back to Newsroom